Want to see CORT full AI Analyst Report?
CORT Stock Chart & Stats
$46.16
$0.08(0.16%)
At close: 4:00 PM EST
$46.16
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$28.66 - $95.11
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.04M
Market Cap
$9.72B
Enterprise Value$3.88K
Total Cash (Recent Filing)$338.18M
Total Debt (Recent Filing)$9.64M
Price to Earnings (P/E)201.2
Beta0.51
Next Earnings
Aug 05, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding107,351,590
10 Day Avg. Volume1,194,479
30 Day Avg. Volume1,036,922
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$97.50Price Target Upside111.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.59
Revenue Forecast (FY)$976.58M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and sizable equity provide durable financial optionality: supports continued R&D, commercialization of recent launches, and tactical investments without immediate capital markets access. That cushion reduces insolvency risk and underpins multi-year execution flexibility.
High Gross Margins And Cash GenerationNear‑zero cost of goods sold gives Corcept durable operating leverage as volumes grow: high gross margins enable reinvestment into launches and pipeline even if SG&A/R&D rise. Historically strong cash flow funds development and commercialization without reliance on external financing.
Diversifying Pipeline & Commercial TractionFDA approval plus large survival benefit and early uptake meaningfully diversify revenue beyond Korlym. Combined oncology and endocrine readouts, plus relacorilant regulatory progress, create multiple sustainable growth drivers and enlarge the addressable market over several years.
Bears Say
Profitability CompressionMaterial margin erosion reduces internal funding capacity and compresses returns on equity. If operating expenses for launches and trials stay elevated while margins remain depressed, the company may need to constrain investment, extend cash runway, or seek external capital, weakening long‑term flexibility.
Operational Scaling & Payer FrictionRecurring payer reauthorizations and pharmacy-network limits create durable revenue recognition lags and higher distribution costs. Persistent backlogs can depress reported sales, raise patient attrition risk, and require sustained investment in specialty distribution to realize projected demand.
Tolerability And Trial Execution Risk (DAZALS)Tolerability-driven discontinuations can slow enrollment, impair adherence and complicate regulatory review. Needing additional dose‑finding before Phase III increases timeline and execution risk, potentially delaying an important diversification avenue and compressing medium‑term growth visibility.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $28.66 and its highest was $95.11 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $9.72B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 16 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.19.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.01.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 107,351,590 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 10.533%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.50 (111.22% Upside)
$97.50 (111.22% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 127.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.73%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
CORT Stock 12 Month Forecast
Average Price Target
$97.50
▲(111.22% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
10.87% Insiders
15.08% Mutual Funds
0.14% Other Institutional Investors
52.07% Public Companies and Individual Investors